Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Castle Biosciences's price to book ratio was 2.2× on Nov 11, 2026, against 2.5× a year earlier. Over the last 5 years it ranged from 1.0× to 2.8×, with a median of 1.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | −0.2 |
| 2025 | Dec 31, 2025 | 2.4× | +0.7 |
| 2024 | Dec 31, 2024 | 1.7× | +0.2 |
| 2023 | Dec 29, 2023 | 1.5× | −0.0 |
| 2022 | Dec 30, 2022 | 1.5× | −1.1 |
| 2021 | Dec 31, 2021 | 2.6× | −5.4 |
| 2020 | Dec 31, 2020 | 8.0× | +0.9 |
| 2019 | Dec 31, 2019 | 7.1× | – |
See a number that looks wrong?